Pfizer Inc. Q2 2026 Earnings Recap

Pfizer’s shares rose 3.1% following Q2 2026 results, driven primarily by raised revenue guidance and strong growth in acquired product portfolios, signaling investor approval of the company’s strategic execution and pipeline progress.

Key Takeaways

• Raised full-year 2026 revenue guidance midpoint, while reaffirming adjusted diluted EPS guidance.
• Acquired product revenues grew 25% operationally year-over-year, excluding prior year’s one-time items.
• Legacy Seagen U.S. portfolio advanced with 21% year-over-year revenue growth, adjusting for onetime stocking.
• Pipeline progress includes 3 regulatory approvals, 6 key data readouts, and 8 pivotal study starts in first half of 2026.
• Cost savings initiatives updated with an additional $1 billion from realignment and $3 billion total expected from manufacturing optimization through 2029.